$12.2 Billion is the total value of Baker Brothers Advisors's 93 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 18.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Seattle Genetics, Inc. | $2,892,270,000 | -26.5% | 51,046,060 | 0.0% | 23.68% | -8.7% | |
| INCY | Buy | Incyte Corporation | $2,178,060,000 | -7.9% | 34,251,607 | +0.0% | 17.84% | +14.4% |
| BGNE | BeiGene, Ltd.sponsored adr | $1,677,485,000 | -18.6% | 11,959,824 | 0.0% | 13.74% | +1.2% | |
| ALXN | Alexion Pharmaceuticals, Inc. | $833,002,000 | -30.0% | 8,555,894 | 0.0% | 6.82% | -12.9% | |
| GHDX | Sell | Genomic Health, Inc. | $756,432,000 | -21.9% | 11,744,010 | -14.8% | 6.19% | -2.9% |
| BMRN | Buy | BioMarin Pharmaceutical Inc. | $646,228,000 | -12.1% | 7,589,294 | +0.1% | 5.29% | +9.2% |
| ACAD | Buy | ACADIA Pharmaceuticals Inc. | $642,173,000 | +8.8% | 39,713,842 | +39.6% | 5.26% | +35.2% |
| AMRN | Buy | Amarin Corporation plcsponsored adr | $579,688,000 | +4.6% | 42,592,824 | +25.0% | 4.75% | +30.0% |
| ASND | Ascendis Pharma A/Ssponsored adr | $177,760,000 | -11.6% | 2,837,352 | 0.0% | 1.46% | +10.0% | |
| MDGL | Madrigal Pharmaceuticals, Inc. | $131,801,000 | -47.4% | 1,169,278 | 0.0% | 1.08% | -34.6% | |
| HRTX | Sell | Heron Therapeutics, Inc. | $130,170,000 | -18.2% | 5,018,104 | -0.1% | 1.07% | +1.7% |
| BCRX | BioCryst Pharmaceuticals, Inc. | $121,882,000 | +5.8% | 15,103,081 | 0.0% | 1.00% | +31.5% | |
| MRTX | Mirati Therapeutics, Inc. | $106,621,000 | -9.9% | 2,513,462 | 0.0% | 0.87% | +11.9% | |
| ARGX | argenx SEsponsored adr | $97,949,000 | +26.7% | 1,019,557 | 0.0% | 0.80% | +57.6% | |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | $84,270,000 | +10.2% | 3,000,000 | 0.0% | 0.69% | +36.9% | |
| RYTM | Rhythm Pharmaceuticals, Inc. | $72,796,000 | -7.9% | 2,708,200 | 0.0% | 0.60% | +14.6% | |
| ARRY | Sell | Array BioPharma Inc. | $71,844,000 | -16.4% | 5,041,696 | -10.9% | 0.59% | +3.9% |
| KOD | New | Kodiak Sciences Inc. | $64,930,000 | – | 9,145,115 | +100.0% | 0.53% | – |
| New | Neurocrine Biosciences, Inc.note 2.25% 5/15/2024 | $63,434,000 | – | 53,270,000 | +100.0% | 0.52% | – | |
| CERS | Cerus Corporation | $54,502,000 | -29.7% | 10,749,937 | 0.0% | 0.45% | -12.7% | |
| ONCE | Spark Therapeutics, Inc. | $54,175,000 | -28.2% | 1,384,130 | 0.0% | 0.44% | -10.7% | |
| NBIX | Sell | Neurocrine Biosciences, Inc. | $52,155,000 | -55.1% | 730,355 | -22.7% | 0.43% | -44.2% |
| PRNB | Principia Biopharma Inc. | $48,968,000 | -6.3% | 1,787,807 | 0.0% | 0.40% | +16.6% | |
| CMTA | Buy | Clementia Pharmaceuticals Inc. | $43,799,000 | +103.1% | 3,724,445 | +92.6% | 0.36% | +152.8% |
| NVTA | Sell | Invitae Corporation | $43,161,000 | -69.3% | 3,902,421 | -53.5% | 0.35% | -61.9% |
| GWPH | Buy | GW Pharmaceuticals plcads | $41,717,000 | -39.1% | 428,345 | +8.0% | 0.34% | -24.2% |
| CBAY | CymaBay Therapeutics, Inc. | $38,702,000 | -29.0% | 4,917,700 | 0.0% | 0.32% | -11.7% | |
| TCDA | Tricida, Inc. | $37,728,000 | -22.8% | 1,600,000 | 0.0% | 0.31% | -4.0% | |
| DBVT | DBV Technologies S.A.sponsored adr | $35,371,000 | -71.4% | 5,509,560 | 0.0% | 0.29% | -64.4% | |
| ZYME | Buy | Zymeworks Inc. | $25,080,000 | +21.8% | 1,708,472 | +30.3% | 0.20% | +50.7% |
| INSM | Insmed Incorporated | $24,298,000 | -35.1% | 1,851,982 | 0.0% | 0.20% | -19.4% | |
| AQXP | Aquinox Pharmaceuticals, Inc. | $23,618,000 | -26.3% | 10,934,154 | 0.0% | 0.19% | -8.5% | |
| BOLD | Buy | Audentes Therapeutics, Inc. | $19,411,000 | +24.7% | 910,463 | +131.5% | 0.16% | +54.4% |
| QURE | uniQure N.V. | $17,436,000 | -20.8% | 605,000 | 0.0% | 0.14% | -1.4% | |
| KRYS | Buy | Krystal Biotech, Inc. | $16,306,000 | +708.8% | 784,674 | +584.3% | 0.13% | +930.8% |
| MRUS | Merus N.V. | $16,240,000 | -29.1% | 1,160,014 | 0.0% | 0.13% | -11.9% | |
| AIMT | Aimmune Therapeutics, Inc. | $16,120,000 | -12.3% | 673,908 | 0.0% | 0.13% | +9.1% | |
| XNCR | Sell | Xencor, Inc. | $15,917,000 | -32.2% | 440,186 | -26.9% | 0.13% | -16.1% |
| SLDB | Solid Biosciences Inc. | $15,755,000 | -43.2% | 587,884 | 0.0% | 0.13% | -29.5% | |
| MYOK | Sell | MyoKardia, Inc. | $15,403,000 | -33.9% | 315,243 | -11.7% | 0.13% | -17.6% |
| ABEO | Sell | Abeona Therapeutics Inc. | $15,017,000 | -46.3% | 2,103,164 | -3.7% | 0.12% | -33.2% |
| RARX | Buy | Ra Pharmaceuticals, Inc. | $14,981,000 | +365.4% | 823,113 | +362.5% | 0.12% | +485.7% |
| New | BioMarin Pharmaceutical Inc.note 0.599% 8/1/2024 | $14,911,000 | – | 15,000,000 | +100.0% | 0.12% | – | |
| IDRA | Buy | Idera Pharmaceuticals, Inc. | $13,396,000 | -68.9% | 4,836,237 | +0.0% | 0.11% | -61.3% |
| AGLE | Buy | Aeglea BioTherapeutics, Inc. | $12,835,000 | -3.4% | 1,713,604 | +23.5% | 0.10% | +20.7% |
| SGMO | Sell | Sangamo Therapeutics, Inc. | $11,478,000 | -47.3% | 999,823 | -22.1% | 0.09% | -34.3% |
| CFRX | ContraFect Corporation | $10,944,000 | -26.1% | 7,153,076 | 0.0% | 0.09% | -8.2% | |
| NVAX | Novavax, Inc. | $8,682,000 | -2.1% | 4,718,318 | 0.0% | 0.07% | +22.4% | |
| MRKR | New | Marker Therapeutics, Inc. | $8,325,000 | – | 1,500,000 | +100.0% | 0.07% | – |
| BLCM | Bellicum Pharmaceuticals, Inc. | $7,819,000 | -52.6% | 2,677,818 | 0.0% | 0.06% | -41.3% | |
| ANAB | AnaptysBio, Inc. | $7,214,000 | -36.1% | 113,086 | 0.0% | 0.06% | -20.3% | |
| IFRX | InflaRx N.V. | $6,510,000 | +6.0% | 178,987 | 0.0% | 0.05% | +32.5% | |
| SBPH | Spring Bank Pharmaceuticals, Inc. | $6,371,000 | -13.8% | 613,144 | 0.0% | 0.05% | +6.1% | |
| ALBO | Albireo Pharma, Inc. | $6,133,000 | -25.6% | 250,000 | 0.0% | 0.05% | -7.4% | |
| CPRX | Catalyst Pharmaceuticals, Inc. | $5,568,000 | -49.2% | 2,900,000 | 0.0% | 0.05% | -36.1% | |
| AUTL | Sell | Autolus Therapeutics plcspon ads | $5,148,000 | -28.7% | 156,773 | -33.4% | 0.04% | -12.5% |
| HALO | Sell | Halozyme Therapeutics, Inc. | $4,389,000 | -46.3% | 299,969 | -33.3% | 0.04% | -33.3% |
| FTSV | Forty Seven, Inc. | $3,930,000 | +5.4% | 250,000 | 0.0% | 0.03% | +28.0% | |
| BLUE | Sell | bluebird bio, Inc. | $3,968,000 | -54.3% | 40,000 | -32.7% | 0.03% | -43.9% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $3,936,000 | +4.7% | 131,250 | 0.0% | 0.03% | +28.0% | |
| XLRN | Acceleron Pharma Inc. | $3,654,000 | -23.9% | 83,900 | 0.0% | 0.03% | -6.2% | |
| ASMB | Assembly Biosciences, Inc. | $3,361,000 | -39.1% | 148,587 | 0.0% | 0.03% | -22.2% | |
| VKTX | Viking Therapeutics, Inc. | $3,251,000 | -56.1% | 425,000 | 0.0% | 0.03% | -44.9% | |
| SYRS | Syros Pharmaceuticals, Inc. | $3,202,000 | -53.2% | 574,835 | 0.0% | 0.03% | -42.2% | |
| MNLO | Menlo Therapeutics Inc. | $2,884,000 | -58.2% | 700,000 | 0.0% | 0.02% | -46.7% | |
| GNMX | Aevi Genomic Medicine, Inc. | $2,765,000 | -43.1% | 3,950,419 | 0.0% | 0.02% | -28.1% | |
| SRRA | New | Sierra Oncology, Inc. | $2,640,000 | – | 2,000,000 | +100.0% | 0.02% | – |
| APLS | Apellis Pharmaceuticals, Inc. | $2,586,000 | -25.8% | 196,078 | 0.0% | 0.02% | -8.7% | |
| GTHX | G1 Therapeutics, Inc. | $2,437,000 | -63.4% | 127,236 | 0.0% | 0.02% | -54.5% | |
| GLPG | Sell | Galapagos NVsponsored adr | $2,300,000 | -91.4% | 25,072 | -89.4% | 0.02% | -89.2% |
| CCXI | Sell | ChemoCentryx, Inc. | $2,259,000 | -56.8% | 207,029 | -50.0% | 0.02% | -47.1% |
| YMAB | Sell | Y-mAbs Therapeutics, Inc. | $2,091,000 | -47.5% | 102,800 | -31.5% | 0.02% | -34.6% |
| ALKS | Sell | Alkermes plc | $1,977,000 | -53.5% | 67,000 | -33.2% | 0.02% | -42.9% |
| ORTX | New | Orchard Therapeutics plcads | $1,966,000 | – | 125,000 | +100.0% | 0.02% | – |
| FOMX | Sell | Foamix Pharmaceuticals Ltd. | $1,788,000 | -54.7% | 498,189 | -27.6% | 0.02% | -42.3% |
| ACHN | Sell | Achillion Pharmaceuticals, Inc. | $1,742,000 | -71.1% | 1,095,359 | -33.2% | 0.01% | -65.0% |
| NTLA | Sell | Intellia Therapeutics, Inc. | $1,755,000 | -68.1% | 128,538 | -33.2% | 0.01% | -61.1% |
| LJPC | La Jolla Pharmaceutical Company | $1,459,000 | -53.1% | 154,675 | 0.0% | 0.01% | -42.9% | |
| ADMS | Adamas Pharmaceuticals, Inc. | $1,474,000 | -57.3% | 172,630 | 0.0% | 0.01% | -47.8% | |
| GLMD | Sell | Galmed Pharmaceuticals Ltd. | $1,473,000 | -66.5% | 215,594 | -33.5% | 0.01% | -58.6% |
| ARAV | New | Aravive, Inc. | $1,423,000 | – | 404,384 | +100.0% | 0.01% | – |
| RCUS | Arcus Biosciences, Inc. | $1,309,000 | -22.7% | 121,534 | 0.0% | 0.01% | 0.0% | |
| MTEM | Molecular Templates, Inc. | $1,027,000 | -25.0% | 254,230 | 0.0% | 0.01% | -11.1% | |
| Trillium Therapeutics Inc. | $864,000 | -70.5% | 505,262 | 0.0% | 0.01% | -63.2% | ||
| INFI | Infinity Pharmaceuticals, Inc. | $685,000 | -56.5% | 580,400 | 0.0% | 0.01% | -40.0% | |
| DVAX | Dynavax Technologies Corporation | $686,000 | -26.2% | 75,000 | 0.0% | 0.01% | 0.0% | |
| PRTO | Proteon Therapeutics, Inc. | $678,000 | +16.5% | 298,591 | 0.0% | 0.01% | +50.0% | |
| AQST | Aquestive Therapeutics, Inc. | $627,000 | -64.0% | 99,600 | 0.0% | 0.01% | -54.5% | |
| AFMD | Affimed N.V. | $622,000 | -28.5% | 200,000 | 0.0% | 0.01% | -16.7% | |
| CNST | Constellation Pharmaceuticals, Inc. | $535,000 | -40.4% | 133,333 | 0.0% | 0.00% | -33.3% | |
| FLGT | Fulgent Genetics, Inc. | $396,000 | -19.3% | 125,000 | 0.0% | 0.00% | 0.0% | |
| SNSS | Sunesis Pharmaceuticals, Inc. | $231,000 | -79.2% | 556,665 | 0.0% | 0.00% | -71.4% | |
| RTTR | Ritter Pharmaceuticals, Inc. | $168,000 | -67.8% | 279,999 | 0.0% | 0.00% | -66.7% | |
| OVID | Exit | Ovid Therapeutics Inc. | $0 | – | -222,139 | -100.0% | -0.01% | – |
| VSAR | Exit | Versartis, Inc. | $0 | – | -2,426,310 | -100.0% | -0.02% | – |
| ARWR | Exit | Arrowhead Pharmaceuticals, Inc. | $0 | – | -307,496 | -100.0% | -0.04% | – |
| MNTA | Exit | Momenta Pharmaceuticals, Inc. | $0 | – | -308,500 | -100.0% | -0.05% | – |
| ERYP | Exit | ERYTECH Pharma S.A.sponsored adr | $0 | – | -1,085,969 | -100.0% | -0.06% | – |
| Exit | BioMarin Pharmaceutical Inc.note 0.75% 10/15/2018 | $0 | – | -12,228,000 | -100.0% | -0.08% | – | |
| Exit | BioMarin Pharmaceutical Inc.note 0.599% 8/1/2024 | $0 | – | -15,000,000 | -100.0% | -0.10% | – | |
| Exit | Neurocrine Biosciences, Inc.note 2.25% 5/15/2024 | $0 | – | -10,000,000 | -100.0% | -0.11% | – | |
| Exit | Corsicanto II Designated Activity Companynote 3.5% 1/5/2047 | $0 | – | -10,000,000 | -100.0% | -0.28% | – | |
| ECYT | Exit | Endocyte, Inc. | $0 | – | -2,548,069 | -100.0% | -0.30% | – |
| SAGE | Exit | Sage Therapeutics, Inc. | $0 | – | -567,497 | -100.0% | -0.53% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-13
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.